Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non—small cell lung cancer (NSCLC).

Garassino says that the future of immunotherapy in NSCLC lies in combinations.

In the future, treatment will be based on phenotype, says Garissino. The 3 phenotypes that are known right now in NSCLC are inflamed and immune-excluded, and immune-desert.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non-small cell lung cancer. 

Dr. Garissino on Combinations With Immune Checkpoint Inhibitors in NSCLC